Board

Alan Reade - Executive Chairman

Mr Reade was appointed on May 25, 2007. He is owner of Global Strategy Expression Limited, a consulting and advisory services business in the life sciences industry. From 2000 until his retirement in 2005, he served as executive chairman of Merial Limited, a leading animal health company and joint venture between Merck & Co. Inc. and Sanofi- Aventis. Earlier in his career he was head of global integration at Aventis, where he was in charge of merger integration, and Chief Executive Officer and member of the Global at Rhone-Poulenc Inc. previously has been a director of Sygen International and IFAH, a global animal health association as well as more than 40 Merial subsidiaries.

He is chairman of the Remuneration Committee and member of the Nominations Committee .

James Hills - Non-executive Director

Mr Hills was appointed on July 09, 2010. He spent the early portion of his career with The Gillette Company and Coca Cola USA where he held senior positions in both sales and brand management. Later, he became a 50% partner and Chief Executive Officer of Weatherly Consumer Products Inc. (Jobe's), a company which developed, branded and marketed specialty fertilizers in North America and Europe. Following the sale of that business in 1996, he and a partner started Gulfstream Home & Garden, Inc., a company which is specialised in the branding of specialist insecticide products for home and garden use which they sold in 2005, following nearly ten years of rapid growth.

Barrington Marshall Riley - Independent Non-executive Director

Mr. Riley was appointed on May 25, 2007. After qualifying as a Chartered Accountant, he joined the Bowater Organization, where he had responsibility for the finance function at several operations. From there he moved to FMC Corporation, the U.S. conglomerate where he had finance and general management responsibilities for a specialty chemical operation, and also oversaw the head office finance function for all UK operations. He joined Proteus International Plc in 1995 as Finance Director and was closely involved in the merger with Therapeutic Antibodies Inc. in 1999, which became Protherics Plc where he was Finance Director until 2007.

He is chairman of the Audit Committee and member of the Nominations Committee.

Patrick Regan - Non-executive Director

Mr Regan was appointed on September 15, 2009. He has been employed as a senior managing director for Laurus Capital Management LLC for over 8 years. Mr. Regan also serves the same role for Valens Capital Management, LLC since its establishment in 2007. Prior to joining Laurus in 2001, Mr. Regan was an associate at Tower Hill Capital Group, an investment banking boutique and venture capital firm for two years. Prior to this, Mr. Regan spent four years as a financial analyst at Geller & Company, afinancial services accounting firm primarily providing CFO functions to private companies and financial planning for high net worth individuals. While at Geller, Mr. Regan completed and received his CPA certification (which he no longer maintains) and was involved in private placement financing, management consulting and general corporate finance functions. Mr. Regan received his B.S. in Business and Economics from Lehigh University in 1994 and his M.B.A. from Fordham University in 2000.

Keith Bigsby - Chief Financial Officer

Mr. Bigsby was appointed on April 27, 2007. After qualifying as a Chartered Accountant, Mr. Bigsby has had over 30 years of senior financial management and board room experience in the technology sector. He has held senior finance positions across Europe, the USA and the Far East, a significant proportion of which has been as Chief Financial Officer (including for publicly listed companies) most recently at Geotrupes Energy Plc and Tadpole Technology Plc. Prior to this he was for six years the European Regional CFO for Wang and held Regional Finance Director roles in the UK and France for Sun Microsystems. He has a significant background in complex business environments, strategic planning and process re-engineering.